Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine.
about
Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational studyOverview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Predicting response to lithium in mood disorders: role of genetic polymorphisms.Quantification of morphine and its major metabolites M3G and M6G in antemortem and postmortem samples.Oral-parenteral conversion factor for morphine in palliative cancer care: a prospective randomized crossover pilot studyInfluence of morphine on pericyte-endothelial interaction: implications for antiangiogenic therapySerum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study.Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.The role of mu opioid receptors in psychomotor stimulation and conditioned place preference induced by morphine-6-glucuronideRole of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10Genetic variability and clinical efficacy of morphine.Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts.Prevalence of UDP-glucuronosyltransferase polymorphisms (UGT1A6∗2, 1A7∗12, 1A8∗3, 1A9∗3, 2B7∗2, and 2B15∗2) in a Saudi population.Pharmacokinetic and pharmacodynamic modeling for acute and chronic pain drug assessment.Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers.Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty.The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.Adult cancer pain.Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation.In silico (computed) modelling of doses and dosing regimens associated with morphine levels above international legal driving limits.Toxicology of Specific Substances
P2860
Q24791044-EE702839-518C-4969-BB98-6488E26AC550Q34635638-EFB440A4-11F5-4AB6-9B0A-2F901EEFFDBCQ35058020-28BE5F93-BFED-49B2-B376-9CBF6F9AF0AFQ35264107-E14F2EFF-CCA2-434B-B5F5-58FDAE0DD2B4Q35391296-93582493-9D36-4556-9C37-B2E48D265742Q35725355-DCB2807B-5A35-4981-B951-300DEDE8B9C2Q35823710-6B0A7D2B-81A6-467D-9C73-07D946D6AABEQ35827481-FA6043BD-909A-48A0-9040-78FE155D84A9Q35871222-85AF934C-F38F-4046-A809-C5312FAC79BAQ36174250-3A09246C-1CA9-408E-8C4B-96E79ADFB91AQ36207969-9098EBC7-BC9E-40FF-A468-19A69F3D216FQ36428066-FAB98577-1858-443C-80D9-3BB9EE3C03FAQ37707406-AC88DA84-7BB2-4299-B028-790EB72A9A82Q38178739-506FD8E2-AE60-4251-BC9A-0DF511539F29Q39395812-A4E097D4-12E2-4CDF-836A-FDF7655CBF3FQ43243208-7E3C9555-9E4F-450B-A7A2-94D6D66308B0Q43968416-739BC193-9188-4290-8081-9B69FC57914FQ43997719-EBCD5045-CA48-4182-92FF-D287F8B6673AQ44331545-81BB1690-2BB9-4E94-88C2-21AD83506DC9Q44347117-B846A3C5-64D6-4C90-A76A-2F7826D66745Q44426953-81F398AC-3C1C-4A80-B77C-53C006A72865Q44476215-ABEB741F-DF9B-4969-B987-EECC49ED1719Q44862502-39AC8C91-3726-4763-9E26-5C74AFEFC7E3Q51391081-80A9E88C-6D60-4780-B9C0-F3327096B264Q53069041-9517F4F6-2ADA-43E8-8F23-E8967C5676D4Q57986556-E47100F6-50D0-4807-B456-236DFA66E8E4
P2860
Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Start of oral morphine to canc ...... nalgesia produced by morphine.
@en
Start of oral morphine to canc ...... nalgesia produced by morphine.
@nl
type
label
Start of oral morphine to canc ...... nalgesia produced by morphine.
@en
Start of oral morphine to canc ...... nalgesia produced by morphine.
@nl
prefLabel
Start of oral morphine to canc ...... nalgesia produced by morphine.
@en
Start of oral morphine to canc ...... nalgesia produced by morphine.
@nl
P356
P1476
Start of oral morphine to canc ...... nalgesia produced by morphine.
@en
P2093
P C Borchgrevink
P2888
P304
P356
10.1007/S002280050003
P577
2000-01-01T00:00:00Z